Premium
Intraperitoneal recombinant interferon‐alpha 2b for recurrent malignant ascites due to ovarian cancer
Author(s) -
Bezwoda Werner Robert,
Seymour Leslie,
Dansey Roger
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890901)64:5<1029::aid-cncr2820640511>3.0.co;2-#
Subject(s) - ascites , medicine , ovarian cancer , intraperitoneal injection , alpha interferon , alpha (finance) , cancer , gastroenterology , interferon , immunology , surgery , construct validity , patient satisfaction
Thirteen patients with malignant ascites due to recurrent ovarian cancer were treated with intraperitoneal interferon 2b (5 mu/m 2 escalating to 15 mu/m 2 , administered twice weekly by indwelling intraperitoneal catheter). The study population included eight patients with ascites only and five patients with ascites plus tumor masses > 2 cm in diameter. Five of 13 responded to treatment. All the responses were seen in patients with ascites only. Although tumor mass was an important determinant of response there was also a correlation between clinical response and suppression of colony growth on soft agar after in vitro exposure of tumor cells to interferon‐alpha (IFNα). The intraperitoneal use of IFNα should be explored further in tumors with a predominant intraperitoneal location and microimplantation growth pattern.